The suggestion of targeting these axes to treat diseases associated with obesity is now being considered, i.e. by administering MDM4 inhibitors (Kon et al., 2018) or targeting these MDM2 partnerships (Liu et al., 2017). Here, MDM4 is linked to obesity disorder.